Kobayashi Pharmaceutical Co., Ltd. (TYO: 4967)
Japan
· Delayed Price · Currency is JPY 5,718.00
-17.00 (-0.30%)
Oct 10, 2024, 3:15 PM JST
Kobayashi Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 18,749 | 27,559 | 27,950 | 27,636 | 26,635 | 26,804 | Upgrade
|
| Depreciation & Amortization | 7,124 | 6,057 | 5,358 | 4,835 | 4,106 | 4,127 | Upgrade
|
| Loss (Gain) From Sale of Assets | 120 | 118 | 121 | 378 | 1,186 | 1,803 | Upgrade
|
| Loss (Gain) From Sale of Investments | -436 | -436 | 89 | -84 | -261 | -315 | Upgrade
|
| Other Operating Activities | -7,915 | -8,359 | -8,007 | -8,396 | -7,900 | -7,787 | Upgrade
|
| Change in Accounts Receivable | 4,612 | -3,781 | 8,296 | -1,523 | 1,588 | -1,426 | Upgrade
|
| Change in Inventory | -1,243 | -3,175 | -1,977 | -462 | 1,309 | -1,020 | Upgrade
|
| Change in Accounts Payable | -7,561 | 361 | 515 | -158 | -4,178 | -1,819 | Upgrade
|
| Change in Other Net Operating Assets | 3,186 | 16 | -431 | 193 | 1,501 | -278 | Upgrade
|
| Operating Cash Flow | 16,636 | 18,360 | 31,914 | 22,419 | 23,986 | 20,089 | Upgrade
|
| Operating Cash Flow Growth | -18.21% | -42.47% | 42.35% | -6.53% | 19.40% | 0.41% | Upgrade
|
| Capital Expenditures | -26,861 | -12,756 | -14,747 | -3,663 | -3,795 | -4,379 | Upgrade
|
| Sale of Property, Plant & Equipment | 6 | 5 | 3 | 10 | 15 | 47 | Upgrade
|
| Cash Acquisitions | -11,176 | -11,176 | - | - | -11,355 | -1,054 | Upgrade
|
| Divestitures | - | - | - | 200 | - | 293 | Upgrade
|
| Sale (Purchase) of Intangibles | -599 | -813 | -1,482 | -522 | -354 | -425 | Upgrade
|
| Investment in Securities | 12,460 | 5,395 | 2,168 | 12,095 | 2,838 | 379 | Upgrade
|
| Other Investing Activities | -202 | -231 | -254 | -129 | -5 | 237 | Upgrade
|
| Investing Cash Flow | -26,372 | -19,576 | -14,312 | 7,991 | -12,656 | -5,072 | Upgrade
|
| Short-Term Debt Repaid | - | - | -1 | -12 | -5 | -495 | Upgrade
|
| Long-Term Debt Repaid | - | - | - | - | - | -570 | Upgrade
|
| Total Debt Repaid | - | - | -1 | -12 | -5 | -1,065 | Upgrade
|
| Net Debt Issued (Repaid) | - | - | -1 | -12 | -5 | -1,065 | Upgrade
|
| Repurchase of Common Stock | -12,000 | -12,000 | -14,056 | -3,943 | - | -8,014 | Upgrade
|
| Dividends Paid | -7,583 | -7,223 | -6,509 | -6,251 | -5,784 | -5,333 | Upgrade
|
| Other Financing Activities | -257 | -240 | -193 | -171 | -230 | -169 | Upgrade
|
| Financing Cash Flow | -19,840 | -19,463 | -20,759 | -10,377 | -6,019 | -14,581 | Upgrade
|
| Foreign Exchange Rate Adjustments | 1,163 | 890 | 673 | 797 | -425 | -79 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | -22 | - | -2 | -1 | Upgrade
|
| Net Cash Flow | -28,413 | -19,789 | -2,506 | 20,830 | 4,884 | 356 | Upgrade
|
| Free Cash Flow | -10,225 | 5,604 | 17,167 | 18,756 | 20,191 | 15,710 | Upgrade
|
| Free Cash Flow Growth | - | -67.36% | -8.47% | -7.11% | 28.52% | -5.29% | Upgrade
|
| Free Cash Flow Margin | -5.91% | 3.23% | 10.33% | 12.08% | 13.41% | 9.35% | Upgrade
|
| Free Cash Flow Per Share | -136.40 | 73.89 | 222.57 | 240.08 | 258.32 | 200.34 | Upgrade
|
| Cash Interest Paid | 28 | 22 | 18 | 17 | 15 | 12 | Upgrade
|
| Cash Income Tax Paid | 7,916 | 8,358 | 8,003 | 8,464 | 7,972 | 7,829 | Upgrade
|
| Levered Free Cash Flow | -10,867 | 2,535 | 11,183 | 14,511 | 15,043 | 14,406 | Upgrade
|
| Unlevered Free Cash Flow | -10,845 | 2,553 | 11,194 | 14,522 | 15,056 | 14,419 | Upgrade
|
| Change in Net Working Capital | 5,938 | 5,952 | -5,499 | 2,347 | 1,032 | 1,285 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.